文献速递心外重症与机械循环支持

左心室辅助装置支持期间血管性血友病因子降解量化标准化方法探索

Toward a Standard Practice to Quantify von Willebrand Factor Degradation During Left Ventricular Assist Device Support.
PubMed 文献 · Ann Thorac Surg · 2020-11-20

该研究纳入48例左心室辅助装置(LVAD)患者,配对比较支持前与支持1周后的血样,评估4种量化血管性血友病因子(VWF)多聚体降解的方法。所有方法均显示LVAD支持期间VWF显著降解,但仅方法1(VWF长度)在出血者与非出血者间显示显著差异。结论强调需建立标准化方法以评估出血风险并指导抗栓治疗。

要点

  • LVAD支持导致VWF多聚体降解,4种量化方法均能检出显著变化。
  • 仅方法1(VWF长度)显示出血者VWF多聚体减少程度显著大于非出血者。
  • 需共识方法标准化VWF降解评估,以指导抗凝抗血小板治疗。

核心结论

  • 需要标准化方法量化机械循环支持设备的VWF多聚体降解。
  • 新方法1成功量化LVAD支持期间患者特异性VWF多聚体长度变化,并显示出血者与非出血者间差异。
  • 采纳共识方法将有助于标准化患者特异性出血风险、指导抗凝和抗血小板治疗及评估LVAD血液相容性。

研究设计与样本

  • 前瞻性配对样本研究,纳入48例LVAD患者,支持前及支持1周后采集血样。
  • 随访652±59天后,将患者分为出血者(≥1次出血事件)与非出血者。
  • 采用电泳和免疫印迹(金标准)分离VWF多聚体,评估4种量化方法。

主要发现

  • 方法1(VWF长度):48/48例患者VWF长度减少-10%±1%,P<.0001。
  • 方法2(VWF密度):40/48例减少-34%(四分位距-46%至-8%),P<.0001。
  • 方法3(支持前/支持比值):46/48例从17±5降至10±1,P<.0001。
  • 方法4(LVAD/支持前指数):46/48例为57%(四分位距50%至73%),P<.0001。
  • 出血发生在27/48例患者;方法1显示出血者VWF多聚体减少-11%±1% vs 非出血者-8%±1%,P=.01,其他方法未显示此关系。

临床怎么用

  • 方法1可量化LVAD支持期间患者特异性VWF多聚体长度变化,或有助于识别出血高风险患者。
  • 标准化VWF降解量化方法有望指导LVAD患者的抗凝和抗血小板治疗。

局限性

  • 样本量有限(n=48),随访时间固定(652±59天),需更大样本验证。
  • 仅方法1显示出血者与非出血者差异,其他方法未显示临床关系。
  • 尚未建立共识标准化方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous-flow left ventricular assist devices (LVADs) cause degradation of von Willebrand factor (VWF) multimers and bleeding. Multiple techniques exist to characterize VWF deficiency. However, a standard methodology has not been established in LVAD patients. Toward this goal, we evaluated 4 methods to quantify VWF multimers. METHODS: We collected paired blood samples from patients (n = 48) before and after 1 week of LVAD support. After 652 ± 59 days of support, patients were classified as bleeders (≥1 bleeding episode) or nonbleeders. VWF multimers were resolved with electrophoresis and immunoblotting, the gold-standard to evaluate VWF multimers. We evaluated 4 quantification methods. RESULTS: Each method demonstrated significant VWF degradation during LVAD support vs a paired, pre-LVAD sample (method 1, VWF length: 48 of 48 patients, -10% ± 1%, P < .0001; method 2, VWF density: 40 of 48, -34% (interquartile range, -46% to -8%), P < .0001; method 3, pre-LVAD to LVAD ratio: 46 of 48, 17 ± 5: 10 ± 1, P < .0001; method 4, LVAD/pre-LVAD index: 46 of 48, 57% (interquartile range, 50% to 73%), P < .0001). Bleeding occurred in 27 of 48 patients. Method 1 demonstrated significantly fewer VWF multimers in bleeders compared with nonbleeders (-11% ± 1% vs -8% ± 1%; P = .01). Other methods did not demonstrate this potentially important clinical relationship. CONCLUSIONS: A standardized methodology is needed to quantify VWF multimer degradation with mechanical circulatory support devices. Novel method 1 successfully quantified the patient-specific change in VWF multimer length during LVAD support and demonstrated a difference in VWF multimers between bleeders and nonbleeders. Adoption of consensus methodology will assist to standardize patient-specific bleeding risk, inform anticoagulation and antiplatelet therapy, and evaluate LVAD hemocompatibility.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Hennessy-Strahs S, Bermudez CA, Acker MA, et al. Toward a Standard Practice to Quantify von Willebrand Factor Degradation During Left Ventricular Assist Device Support. Ann Thorac Surg. 2020. PMID: 33227272. doi:10.1016/j.athoracsur.2020.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。